Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 268

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 268
---
, from the 2021 CLA Maturity Date, 
 during 2023. The number of shares issued upon exercise of the warrant will be calculated by dividing 150.0% of the principal of the 
 2021 Notes by the 2021 CLA Conversion Price. The exercise price of each warrant will be 125.0% of the 2021 CLA Conversion Price.    |

Upon the occurrence of an Exit Event
(IPO or a merger and acquisition), the warrants will be exercisable to the same securities issued to the 2021 Note holders upon conversion
of the 2021 Note at the Mandatory conversion (see Note 6b). The number of shares issued upon exercise of the warrant will be calculated
by dividing 150.0% of the 2021 CLA Amount by the 2021 CLA Conversion Price. The exercise price of each warrant will be 125.0% of the
2021 CLA Conversion price.

<div align='center'>F-19</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY (Cont.) |

On March 11, 2023, following the 2021
Note conversion, the warrants became exercisable into 132,577 preferred D-2 shares at an exercise price of $12.16 per warrant. The warrants
are exercisable until December 31, 2023.

The number of the warrants and exercise
price were adjusted retroactively to reflect the Split, see Note 1c.

The Company estimates the fair value
of the warrant using PWERM. For the years ended December 31, 2023, the Company recorded an income of $5 as change in fair value of the
warrant. On January 1, 2024, the warrants expired as they were not exercised and the Company recorded an income at the amount of $402.

| NOTE 8:- | TAXES ON INCOME |

| a. | Tax rates applicable to the Company: |

| b. | Net operating loss and capital carry forward: |

As of December 31, 2024, the Company
had net operating loss carry forwards and capital loss carry forward for Israeli income tax purposes of approximately $38,940 and $117,
respectively. Net operating loss carry forwards in Israel may be carried forward indefinitely and offset against future taxable
income.